English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective: The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients. Methods: Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria. Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment. Results: At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/ mL)] (p=0.021). During the first 12 weeks of omalizumab therapy, a dramatic decrease in D-dimer levels was observed in serial measurements of CIU/CSU (p=0.001) and also BP patients (p=0.017). Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p<0.001, p=0.278, respectively). Conclusion: Baseline IgE levels may be used to predict which patients will gain benefit from omalizumab therapy in CIU/CSU group. During omalizumab therapy the plasma D-dimer levels show a dramatic decrease in the group of patients who responded of CIU/CSU and BP.

türk dermatoloji dergisi

Effect of Omalizumab Therapy on Coagulation Parameters and Total Immunoglobulin E Levels in Patients with Chronic Idiopathic Urticaria and Bullous Pemphigoid